PediRISE Feasibility
Launched by DANA-FARBER CANCER INSTITUTE · Feb 22, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The PediRISE Feasibility trial is a research study aimed at helping families of children with cancer. The main goal is to see if families are interested in participating in a program called PediRISE, which offers additional support during their child's treatment. Participants will be randomly assigned to one of two groups: one group will receive the PediRISE program, while the other will receive standard care that they would typically get. This study is particularly focused on families facing financial stress and aims to understand how the program can help reduce disparities in care.
To be eligible for this study, children must be under 18 years old, recently diagnosed with cancer, and starting their treatment at one of the participating hospitals. Additionally, families must have a low income and live in Massachusetts, New York, or New Jersey. If you decide to participate, you can expect to be part of a supportive program designed to help you navigate the challenges of cancer treatment. The trial is currently looking for participants, and your involvement could help improve care for future families facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Child diagnosed with de novo cancer
- • Child has established care at a study site and initiated cancer-directed therapy in the prior 2-months
- • Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan
- • Child is \<18 years at time of enrollment
- • Parent/guardian screened positive for self-reported low-income (\<200% FPL).
- • Family primary residence in MA, NY or NJ
- • Provider approval for permission to approach
- Exclusion Criteria:
- • Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy
- • Foreign national family receiving care as an Embassy-pay patient
- • Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, AHOD2131, ANBL2131, DFCI 23-001).
- • Child or household member receiving SSI.
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Kira Bona, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported